Avastin (bevacizumab) is a type of chemotherapy treatment that slows tumor growth by blocking the protein that is responsible for forming new blood vessels, which is what tumors need to thrive. By blocking these blood vessels, tumor growth is slowed. For those suffering from mesothelioma, hindering tumor growth can greatly[…]
Avastin
Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results
Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]
Nintedanib May Surpass Bevacizumab as a More Effective Chemotherapy Treatment for Mesothelioma
In 2016, scientists and researchers were excited to begin Phase II of the clinical trial involving treating patients with malignant pleural mesothelioma with Nintedanib, a triple angiokinase inhibitor designed to hinder protein kinases in cancer cells and stop cancer cells from growing their own blood vessels. The LUME-Meso Phase II[…]
Bevacizumab – A Positive Treatment with Serious Side Effects
Bevacizumab (Avastin) is commonly viewed as chemotherapy treatment because when administered intravenously, it is particularly effective in controlling such illnesses such as lung cancer and colon cancer. However, it is a bit different than traditional chemotherapy treatments, which directly attack cancer cells. Bevacizumab fights cancer cells by cutting off oxygen[…]
Bevacizumab (Avastin): Part of a New Treatment Regimen for Mesothelioma Patients
The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to[…]
Adding an inhibitor to mesothelioma treatment proves effective
A recent mesothelioma study found the addition of bevacizumab to the chemotherapy treatment of pemetrexed plus cisplatin may increase the survival rate in patients. From 2008 to 2014, patients were given the standard treatment in 21-day increments for six cycles, with some receiving bevacizumab. The addition of bevacizumab increased survival[…]
